本文選題：基因多態(tài)性　切入點：麥考酚酸　出處：《中國醫(yī)院藥學雜志》2015年03期 　論文類型：期刊論文

【摘要】：目的:綜述近年來國內外學者對基因多態(tài)性與麥考酚酸(MPA)及其代謝產物藥動學關系的研究,為指導臨床合理用藥提供循證依據(jù)。方法:查閱國內外相關文獻,進行系統(tǒng)的文獻整理和綜合分析。結果:各研究間由于研究對象的病理生理差異、種族差異、突變頻率不同、合并用藥的影響等,研究結果存在差異。其中,可能與MPA及其代謝產物藥動學有關的位點有:UGT2B7 C802T、SLCO1B3 T334G、UGT1A9 T-275A/或C-2152T;存在爭議的位點有:UGT1A8*2、UGT1A9 I399C/T、UGT1A9 C-440T、ABCC2 C-24T、ABCG2 C421A;可能無關的位點有:CES2、SLCO1B1、SLCO2B1、ABCB1 C3435T。結論:基因多態(tài)性可以影響MPA及其代謝產物的藥動學,要進一步闡明基因多態(tài)性與MPA及其代謝產物藥動學的關系,尚需更多高質量、大樣本的體內研究。
[Abstract]:Objective: to review the recent studies on the relationship between gene polymorphism and mycophenolic acid (MPA) and its metabolite pharmacokinetics, and to provide evidence-based evidence for guiding rational drug use in clinical practice. Methods: the relevant literature at home and abroad was reviewed. A systematic literature review and comprehensive analysis were carried out. Results: there were differences in the results of the studies due to the pathophysiological differences, ethnic differences, mutation frequencies and the effects of combined use of drugs. The possible sites associated with MPA and its metabolites pharmacokinetic are: UGT2B7 C802TnSLCO1B3 T334GUGT1A9 T-275A9 or C-2152T; disputed loci UGT1A8A9 I399C / TUGT1A9 C-440TABCC2 C-24TnABCG2C421A; perhaps unrelated loci: CES2SLCO1B1B1ABB1ABCB1SLC3435T.Conclusion: genetic polymorphisms may affect the pharmacokinetics of MPA and its metabolites. In order to further elucidate the relationship between gene polymorphism and pharmacokinetics of MPA and its metabolites, more high quality and large sample in vivo studies are needed.
【作者單位】： 南京軍區(qū)福州總醫(yī)院藥學科;沈陽藥科大學藥學院;
【分類號】：R969

【參考文獻】

相關期刊論文 前2條

1 石磊,蔣沁,李韶菁,張華;微生物來源的免疫抑制劑[J];國外醫(yī)藥(抗生素分冊);2005年05期

2 黃美蘭,冉志華;多藥耐藥相關蛋白基因及其在腫瘤耐藥中的作用[J];胃腸病學;2005年04期

【共引文獻】

相關期刊論文 前8條

1 甘思遠;區(qū)增冠;孫艷芹;陳娟;陳莉熔;;MRP2蛋白在食管鱗癌中的表達及其與化療耐藥的相關性[J];現(xiàn)代生物醫(yī)學進展;2012年25期

2 王霄e，

本文編號：1620810